The peptide library
Every entry states its evidence level and approval status up front. Filter by what the research shows, not by what a product page claims.
Cagrilintide
A long-acting amylin analogue that slows digestion and reduces appetite, studied alone and combined with semaglutide for obesity.
Dulaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes, with proven cardiovascular benefit in people at high risk.
Exenatide
A GLP-1 receptor agonist derived from Gila monster saliva, approved for type 2 diabetes in twice-daily and once-weekly forms.
Liraglutide
A once-daily GLP-1 receptor agonist approved for type 2 diabetes and weight management, and the first in its class shown to reduce cardiovascular events.
Lixisenatide
A once-daily GLP-1 receptor agonist approved for type 2 diabetes, often paired with basal insulin.
Pramlintide
A synthetic amylin analogue licensed in the US as an addition to mealtime insulin in type 1 and type 2 diabetes.
Retatrutide
An investigational triple agonist acting on GIP, GLP-1 and glucagon receptors, with the largest weight loss reported for any peptide in an early trial. Not approved and not available outside studies.
Semaglutide
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. The most thoroughly studied peptide drug in its class.
Tirzepatide
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management, with larger average weight loss than GLP-1-only agonists in trials.